We are live on ! Find out more
CP

Catalys Pacific Portfolio holdings

AUM $229M
1-Year Est. Return 100.3%
This Fund
S&P 500
This Quarter Est. Return
+14.86%
1 Year Est. Return
+100.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$125M
AUM Growth
-$7.1M
Cap. Flow
-$3.55M
Cap. Flow %
-2.83%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$5.6M

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$6.66M
2
HLVX
HilleVax
HLVX
+$2.49M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
1
Mineralys Therapeutics
MLYS
$2.34B
$105M 83.48%
8,644,579
-550,000
-6% -$6.66M
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$678M
$20.3M 16.19%
1,122,572
+400,610
+55% +$5.6M
HLVX
3
DELISTED
HilleVax
HLVX
$416K 0.33%
236,379
-972,595
-80% -$2.49M

Similar funds

CCM
Cloud Capital Management Seattle, Washington $229M AUM 19.91% 1-Year Est. Return
CIS
Custom Index Systems New York $230M AUM 33.6% 1-Year Est. Return
CCP
Cane Capital Partners Saint Francisville, Louisiana $229M AUM
AIA
Alternative Investment Advisors Maitland, Florida $229M AUM 17.2% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return
NIA
NBZ Investment Advisors Knoxville, Tennessee $229M AUM 17.28% 1-Year Est. Return
SCM
Soros Capital Management New York $230M AUM 83.9% 1-Year Est. Return
AF
Abound Financial Granite Bay, California $229M AUM 17.03% 1-Year Est. Return

Catalys Pacific's Q3 2024 Portfolio in Review

As of Q3 2024, Catalys Pacific held 3 positions worth $125M, down 5.4% from $132M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2024: portfolio turnover was 0%. Catalys Pacific opened no new positions and made no exits, leaving the 3-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Catalys Pacific added most to Phathom Pharmaceuticals in Q3 2024, an estimated $5.6M increase.
  • Catalys Pacific's biggest Q3 2024 reduction was Mineralys Therapeutics, cutting an estimated $6.66M.
  • Catalys Pacific's ten largest holdings make up 100% of its $125M portfolio in Q3 2024.
  • Catalys Pacific opened 0 new positions and closed 0 in Q3 2024.
  • Catalys Pacific's portfolio value fell 5.4% quarter-over-quarter to $125M.

Based on Catalys Pacific's 13F filing for Q3 2024, filed 12 Nov 2024.